NEW YORK (GenomeWeb News) – Using whole-genome sequencing in a clinical trial of aromatase-inhibitor therapy for estrogen-positive breast cancer patients, researchers from the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and the Genome Institute at Washington University in St. Louis have found genomic signatures that correlate with drug response and resistance.

The study's results were published online Sunday in Nature.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.